Table 2.
Trial | Interval | Patient number | Mean age (years) | Gender | Interval range | Height from anal verge, cm | Preneoadjuvant therapy stage | pCR% | pCR (n) | P value | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Male | Female | I | II | III | IV | |||||||||
Moore et al. [6] | ≤44 days | 82 | 59 | 52 | 30 | 15∼206 days | 6.1 | 3 | 28 | 51 | 0 | 12 | 10 | 0.19 |
>44 days | 73 | 62 | 46 | 27 | 6.4 | 3 | 21 | 49 | 0 | 19 | 14 | |||
| ||||||||||||||
Tran et al. [7] | ≤8 weeks | 16 | 62.3 | 10 | 6 | 8∼43 weeks | ≤10 (NS) | 0 | 8 | 8 | 0 | 6 | 1 | 0.19 |
>8 weeks | 32 | 58.1 | 18 | 14 | 1 | 18 | 11 | 1 | 9 | 3 | ||||
| ||||||||||||||
Lim et al. [8] | 2∼41 days | 217 | 55.3 | 138 | 79 | 35.6 ± 3.3 days | 4.8 ± 2.1 | 43 (I + II) | 174 | 0 | 13.8 | 30 | 0.74 | |
42∼56 days | 180 | 57.5 | 125 | 55 | 50.1 ± 4.4 days | 4.8 ± 2.1 | 39 (I + II) | 141 | 0 | 15 | 27 | |||
| ||||||||||||||
Tulchinsky et al. [9] | ≤7 weeks | 48 | 59 | 35 | 13 | 13∼173 days | 5.6 | 0 | 39 | 6 | 0 | 16.7 | 8 | 0.03 |
>7 weeks | 84 | 64 | 54 | 30 | 6.2 | 0 | 63 | 17 | 0 | 34.5 | 29 | |||
| ||||||||||||||
Habr-Gama et al. [10] | ≤12 weeks | 121 | 56.9 | 65 | 56 | 9.8 ± 2.2 weeks | 4.1 ± 1.7 | 10 | 50 | 23 | 0 | 13 | 11 | 0.2 |
>12 weeks | 129 | 60 | 83 | 46 | 25.8 ± 12.3 weeks | 3.9 ± 1.8 | 7 | 57 | 25 | 0 | 8 | 6 | ||
| ||||||||||||||
de Campos-Lobato et al. [11] | <8 weeks | 91 | 57 | 129 | 48 | 4∼14 weeks | 5.5 (4–7) | 0 | 53 | 28 | 0 | 16.2 | 13 | 0.027 |
≥8 weeks | 86 | 6 (3–7) | 0 | 50 | 39 | 0 | 31.1 | 28 | ||||||
| ||||||||||||||
Evans et al. [12] | <6 weeks | 18 | 66 | 60 | 35 | 3 days∼24 weeks | NS | NAa | 0 | 27 | NAa | 5.6 | 1 | NA |
6∼8 weeks | 32 | NAa | 6 | 23 | NAa | 12.5 | 4 | |||||||
>8 weeks | 45 | NAa | 10 | 34 | NAa | 17.8 | 8 | |||||||
| ||||||||||||||
Wolthuis et al. [13] | ≤7 weeks | 201 | 64 | 124 | 77 | 28∼103 days | ≤10 | 0 | 27 | 174 | 0 | 15.9 | 32 | 0.006 |
>7 weeks | 155 | 62 | 109 | 46 | 50∼103 days | 0 | 14 | 141 | 0 | 28.4 | 43 | |||
| ||||||||||||||
Sloothaak et al. [14] | <8 weeks | 312 | 63 | 200 | 112 | 1∼80 weeks | NS | 74 (I + II) | 198 (III + IV) | 10.3 | 32 | 0.013 | ||
8∼9 weeks | 511 | 63 | 327 | 184 | 105 (I + II) | 354 (III + IV) | 13.1 | 67 | ||||||
10∼11 weeks | 406 | 64 | 244 | 162 | 68 (I + II) | 306 (III + IV) | 18 | 73 | ||||||
≥12 weeks | 364 | 64 | 229 | 135 | 68 (I + II) | 255 (III + IV) | 11.8 | 43 | ||||||
| ||||||||||||||
Jeong et al. [15] | <8 weeks | 105 | 58.4 | 79 | 26 | 4∼14 weeks | 4.8 ± 2.6 | 6 | 30 | 69 | 0 | 16.2 | 17 | 0.817 |
≥8 weeks | 48 | 56.4 | 38 | 10 | 4.7 ± 2.7 | 3 | 7 | 38 | 0 | 18 | 9 | |||
| ||||||||||||||
Fang et al. [16] | 5∼6 weeks | 32 | NA | NA | NA | NA | mid and low rectal cancer | 0 | 56 | 50 | 0 | 18.8 | 6 | 0.372 |
≥6 weeks | 74 | 12.2 | 9 | |||||||||||
| ||||||||||||||
Calvo et al. [17] | <6 weeks | 136 | 65.5 | 91 | 45 | 4∼8 weeks | 7.0 | 47a | 84a | 8.8 | 12 | 0.34 | ||
≥6 weeks | 199 | 66.0 | 109 | 90 | 7.0 | 45a | 147a | 12.1 | 24 | |||||
| ||||||||||||||
Zeng et al. [18] | ≤7 weeks | 111 | 59 | 62 | 49 | 25–105 days | NS | 32 | 79 | 15.3 | 17 | 0.029 | ||
>7 weeks | 122 | 59 | 68 | 54 | 28 | 94 | 27.1 | 33 | ||||||
| ||||||||||||||
You et al. [19] | ≤7 weeks | 139 | 55 | 96 | 43 | 4–14 weeks | NS | 40 | 99 | 27.3 | 38 | 0.030 | ||
>7 weeks | 152 | 56 | 108 | 44 | 50 | 102 | 29.6 | 45 | ||||||
| ||||||||||||||
Sirohi et al. [20] | ≤60 days | 42 | 50 | 28 | 14 | 6–474 days | 6 | NA | 14 | 6 | 0.24 | |||
>60 days | 68 | 48 | 50 | 18 | 4 (P = 0.045) | 24 | 16 |
awith data missing.
NA: data not available.